Notably, the inhibition of transcriptional repressors such as EZH2 (67, 68) and HDAC3 (66, 69) has been investigated as a strategy to restore MHC-II expression in B cell lymphoma models. Here, HDAC3 is linked to B-cell non-Hodgkin lymphoma.